Transcode Therapeutics Inc RNAZ
$2.97 $0.15 (4.84%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
RNAZ Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Transcode Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Transcode Therapeutics Inc. Stock Analysis RNAZ
United States Health Care Nano Cap TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc (RNAZ) Chart
Financial Metrics & Statements of Transcode Therapeutics Inc (RNAZ)
FAQ's for Transcode Therapeutics Inc (RNAZ)
- As of August 2026, Transcode Therapeutics Inc RNAZ is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Transcode Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Transcode Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Transcode Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Transcode Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Transcode Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Transcode Therapeutics Inc (RNAZ)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
